Tuttle Capital Management’s Aspire Biopharma ASBP Stock Holding History

Tuttle Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14	Closed	-$187K	–	71
2024 Q1	$187K	Hold	14	–	–	1.45%	32
2023 Q4	$185K	Buy	+14	New	+$184K	1.29%	30

Other funds holding ASBP

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tuttle Capital Management's ASBP Position: Q2 2024 in Review

Tuttle Capital Management sold out of Aspire Biopharma (ASBP) in Q2 2024, closing a stake of 14 shares — an estimated $187K sold.

Tuttle Capital Management first reported a position in ASBP in Q4 2023 and held it in 2 quarters. The position peaked at $187K in Q1 2024. 3 funds tracked by Wall St. Rank hold ASBP as of Q2 2024.

Tuttle Capital Management reported no remaining Aspire Biopharma position as of Q2 2024 after selling out during the quarter.
Tuttle Capital Management sold 14 Aspire Biopharma shares in Q2 2024, an estimated $187K.
Tuttle Capital Management first reported a position in Aspire Biopharma in Q4 2023 and held it in 2 quarters.
Tuttle Capital Management's Aspire Biopharma position peaked at $187K in Q1 2024.
3 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2024.

Based on Tuttle Capital Management's 13F filing for Q2 2024, filed 12 Jul 2024.